Pharmaceuticals and Life Sciences
Browse through stories in the life sciences, pharmaceuticals, and biotechnology.
Steve Garbon, The Braff Group Answers the Proust Questionnaire for Dealmakers
This interview features Steve Garbon, Director of Finance at the Braff Group, where he delves into M&A transactions and valuations. [Read More]
What exactly is Amazon scheming in the healthcare sphere?
Amazon continues to stay mum on its healthcare ambitions but if you put the pieces together, it’s clear there’s some sort of play in the works. This past year, rumors... [Read More]
After Constellation Brands: What’s next for the Canadian Cannabis Sector?
The marijuana industry is worth as much as $35 billion per year. As legal restrictions are eased, will this mean M&A activity? [Read More]
Filmaceuticals: PE Firms Partner with Pharma to Develop the Next Blockbuster Drug
As recently noted in a Wall Street Journal article, some private equity (PE) firms have begun partnering with pharmaceutical companies, though in a manner far from traditional. [Read More]
SUBSCRIBE TODAY
Get TOUCHPOINT stories delivered straight to your inbox.
The Art of the Fail: Lessons from the Trumpcare Debacle
As far as daytime dramas go, the the White House Administration’s ongoing challenges in passing its healthcare bill continue to dominate the news and make for “must-see” TV. After years... [Read More]
Prognosis Positive: Pharma and Biotech M&A Outlook
Dealmaking activity in the pharmaceutical and biotechnology industries remained strong in 2016, in contrast to M&A levels in many other sectors. [Read More]
What the failed Pfizer-Allergan deal means for the future of tax inversions
Tax inversions are still legal, but are they still on the way out? Here's what the failed Pfizer-Allergan deal showed us. [Read More]
Monoclonal Antibodies Continue to Drive Biotech Investment
Monoclonal antibodies represent one of the most successful therapeutic drug classes, attracting billions of investment dollars for the biotech industry. [Read More]
